This HTML5 document contains 142 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n12http://dx.doi.org/10.1016/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q33356951
rdf:type
wikibase:Item
schema:description
article scientifique (publié 2003) 2003年论文 ২০০৩-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ мақолаи илмӣ 2003年の論文 مقالة علمية artigo científico (publicado na 2003) artikulong pang-agham tudományos cikk 2003年论文 บทความทางวิทยาศาสตร์ სამეცნიერო სტატია scienca artikolo scientific article επιστημονικό άρθρο articolo scientifico artículo científico publicado en 2003 2003 nî lūn-bûn 2003年論文 سائنسی مضمون наукова стаття, опублікована в жовтні 2003 научни чланак 2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած artigo científico (publicado na 2003) 2003年論文 מאמר מדעי artículu científicu espublizáu en 2003 tieteellinen artikkeli wissenschaftlicher Artikel 2003年论文 vedecký článok teaduslik artikkel 2003年論文 artikull shkencor 2003年论文 artykuł naukowy 2003年论文 научная статья مقالة علمية تنشرت ف 1 أكتوبر 2003 article scientific wetenschappelijk artikel مقالهٔ علمی artigo científico мақолаи илмӣ videnskabelig artikel (udgivet 2003) vetenskaplig artikel vitskapeleg artikkel 2003년 논문 mokslinis straipsnis bilimsel makale article científic vědecký článek articol științific 2003 թվականի հոտեմբերին հրատարակված գիտական հոդված naučni članak научна статия научни чланак 2003年論文 2003年论文 bài báo khoa học 2003年論文 vitenskapelig artikkel
p:P577
wds:Q33356951-CC39EF33-DB3B-49E6-9433-EB19CB0F341F
wdt:P577
2003-10-01T00:00:00Z
p:P2860
wds:Q33356951-E085B432-B4A0-4710-969B-9601E915C76B wds:Q33356951-E5E8995B-2848-4F30-BEE4-16E502694A98 wds:Q33356951-6F7D6A61-E684-4A7F-B72A-DA21662BAA8A wds:Q33356951-837749DE-AF55-4240-977A-BFE73211F899 wds:Q33356951-84859C78-B532-4994-8B46-D0F681F5D130 wds:Q33356951-9542D8E9-D0AA-47BF-A35B-D86E290D8F1D wds:Q33356951-9A04F3C8-6507-40DF-AF00-AF9791A8EAEB wds:Q33356951-C62BFBB6-85E6-4C96-90D7-EBE93D922954 wds:Q33356951-C653A4A8-E55C-4A7F-81A1-C51CB2041372 wds:Q33356951-D498E2CD-7A8E-4DE3-A761-E73031BA4181 wds:Q33356951-0C2A4756-5D59-47E9-A383-4798BCADCDAB wds:Q33356951-21FDD3AF-9DE2-4C98-8EFF-B2A93AA1002B wds:Q33356951-2205D0A7-BCE0-491B-96C4-580224B2B551 wds:Q33356951-38B25198-17EE-4950-8A20-6ADF36D645BE
wdt:P2860
wd:Q72426675 wd:Q31961545 wd:Q68447088 wd:Q29615476 wd:Q33497327 wd:Q33491765 wd:Q44064110 wd:Q54294219 wd:Q73368715 wd:Q43850218 wd:Q72956115 wd:Q29619399 wd:Q33336857 wd:Q33328193
p:P2093
wds:Q33356951-23584287-2544-4F71-B299-46EFF32DE113 wds:Q33356951-5832C3C4-7372-435B-A9F8-6CAF199D39EA wds:Q33356951-59D061D1-73E8-4955-B3A5-55178CA21387 wds:Q33356951-52327CB0-2AE6-4A1D-A0BC-94CCD0C4C1DD wds:Q33356951-550EEFEE-2194-41BB-B538-A6E262606E09 wds:Q33356951-8662C3C3-24EA-4A94-B260-445DD5A85243 wds:Q33356951-90BE5877-3620-4859-9A53-7E04E73D3E3E wds:Q33356951-5F0D61E2-FE7B-4BED-B6EC-88A07B00CABE wds:Q33356951-C7283355-8E16-48B9-9318-E658BB31B8C7 wds:Q33356951-A1DF175B-F523-4508-A5B7-726EEFF9E77A
wdt:P2093
Gary Shapiro KyungMann Kim Tien Hoang Joan H Schiller Anthony Jaslowski Paul Koch James McGovern Maria Quisumbing Peter Beatty Robert Witte
rdfs:label
Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer
skos:prefLabel
Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer
schema:name
Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer
p:P1476
wds:Q33356951-D38FFE76-A1B6-4B67-9BA2-4B999E707BE2
wdt:P1476
Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer
p:P304
wds:Q33356951-E5E8BAA8-33DF-4645-8981-CA998A1E463B
wdt:P304
97-102
p:P31
wds:Q33356951-5BF31F08-289D-4DD8-B06A-E179957EB600
wdt:P31
wd:Q13442814
p:P921
wds:Q33356951-24EBE9DA-4D00-4233-B08C-E6C9B0A940A7
wdt:P921
wd:Q47912
p:P698
wds:Q33356951-5DF93319-4F5A-433C-B7B2-B1BA7D1871B8
wdtn:P698
n9:14512193
wdt:P698
14512193
p:P1433
wds:Q33356951-ED6E7F13-A1C3-4411-B888-5270386EEF5B
wdt:P1433
wd:Q641464
p:P433
wds:Q33356951-136CB799-EAAC-483E-B49E-EBD59C0AF7E6
p:P478
wds:Q33356951-188D0101-BC43-4D4A-AA36-27852DB88CDD
wdt:P433
1
wdt:P478
42
p:P356
wds:Q33356951-B1F0E6B4-2E87-428E-8B00-439528C4B968
wdtn:P356
n12:S0169-5002(03)00273-3
wdt:P356
10.1016/S0169-5002(03)00273-3